Pretreatment minimal staging and prognostic factors for non-small cell lung cancer

Lung Cancer

Volumn 17, Issue SUPPL. 1, 1997, Pages

  Feld, R ^a   Abratt, R ^d   Graziano, S ^b   Jassem, J ^c   Lacquet, L ^d   Ninane, V ^e   Paesmans, M ^d   Rocmans, P ^f   Schiepers, C ^g   Stahel, R ^h   Stephens, R ⁱ  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d Dept of Thorac and Cardiac Surgery ^*

^e SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^f ERASME HOSPITAL   (Belgium)

^g OLIVE VIEW UCLA MEDICAL CENTER   (United States)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

ⁱ MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHOSCOPY; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DIAGNOSTIC VALUE; HUMAN; LUNG NON SMALL CELL CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PROGNOSIS;

EID: 0030916969     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(97)00637-5     Document Type: Conference Paper

References (34)

1. Goldstraw P. Pretreatment minimal staging for non-small cell lung cancer: an updated consensus report. Lung Cancer 1994; 3: S1-S4.
2. Sazon DA, Santiago SM, Soo Hoo GW, Khonsary A, Bron C, Mandelkern M, Blahd W, Williams AJ. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. Am J Resp Crit Care Med 1996; 153: 417-421.
3. Quint LE, Francis IR, Wahl RL, Gross BH, Glazer GM. Preoperative staging of non-small-cell carcinoma of the lung: imaging methods. Am J Roentgenol 1995; 164: 1349-1359.
4. Chin R Jr., Ward R, Keyes JW, Choplin RH, Reed JC, Wallenhaupt S, Hudspeth AS, Haponik EF. Mediastinal staging of non-small-cell lung cancer with positron emission tomography. Am J Resp Crit Care Med 1995; 152: 2090-2096.
5. Moore DF Jr., Lee JS. Staging and prognostic factors: non-small cell lung cancer. Lung Cancer, Principles Practice 1996; 29: 481-494.
6. Graziano SL. Non-small cell lung cancer: clinical value of new biological predictors. Lung Cancer 1997; Suppl 1: S37-S58.
7. Wahl RL, Quint LE, Greenough RL et al. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 1994; 191: 371-377.
8. Sorensen JB. Prognosis and prognostic factors in adenocarcinoma of the lung. Dan Med Bull 1992; 39: 453-463.
9. Simon R. Importance of prognostic factors in cancer clinical trials. Cancer Treat Rep 1984; 68: 1850-192.
10. Sather HN. The use of prognostic factors in clinical trials. Cancer 1986; 58: 461-467.
11. Feld R, Arriagada R, Ball DL, Mattson K, Sorensen JB. Prognostic factors in non-small cell lung cancer: a consensus report. Lung Cancer 1991; 7: 3-5.
12. Feld R, Borges M, Giner V, Ginsberg R, Harper P, Klastersky J, Lacquet L. Paesmans M, Payne D, Rosell R, Sause W, Sculler JP, Shaw E, Sorensen J, Splinter T, Stahel R, Bunn P. Prognostic factors in non-small cell lung cancer. Lung Cancer 1994; 3: S12-S23.
13. Gail MH, Eagan RT, Feld R et al. Prognostic factors in patients with resected stage I non-small cell lung cancer. A report from the Lung Cancer Study Group. Cancer 1984; 54: 1802-1813.
14. Sorensen JB, Babsber JH. Prognostic factors in resected stage I and II adenocarcinoma of the lung. A multivariate regression analysis of 137 consecutive patients. J Thorac Cardiovasc Surg 1990; 99: 218-226.
15. Desiauriers J, Brisson J, Cartier R et al. Carcinoma of the lung: Evaluation of satellite nodules as a factor influencing prognosis after resection. J Thorac Cardiovasc Surg 1989; 97: 504-512.
16. Miller TP, Chen TT, Coltman CA et al. Effect of alternating combination chemotherapy on survival of ambulatory patients with metastatic large-cell and adenocarcinoma of the lung: A Southwest Oncology Group Study. J Clin Oncol 1986; 4: 502-508.
17. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1986; 4: 702-709.
18. O'Conell JP, Kris MG, Gralla RJ et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small cell lung cancer treated with combination chemotherapy. J Clin Oncol 1986; 4: 1604-1614.
19. Sorensen JB, Badsberg JH, Olsen J. Prognostic factors in inoperable adenocarcinoma of the lung: a multivariate regression analysis of 259 patients. Cancer Res 1989; 49: 5748-5754.
20. Albain KS, Crowley JJ, LeBlanc M, Livingstone RB. Survivaldeterminants in extensive stage non-small cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol 1991; 9: 1618-1626.
21. Shinkal T, Eguchi K, Sasaki Y et al. A prognostic-factor risk index in advanced non-small-cell lung cancer treated with cisplatin-containing combination chemotherapy. Cancer Chemother Pharmacol 1992; 30: 1-6.1
22. Kokima A, Chinkai T, Eguchi K et al. Analysis of three year survivors among patients with advanced inoperable non-small cell lung cancer. Jpn J Clin Oncol 1991; 21: 276-281.
23. Mountain CF. A new international staging system for lung cancer. Chest 1986; 89: Suppl 4: 225s-233s.
24. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983; 1: 710-719.
25. Szabo E, Mulshine J. Epidemiology, prognostic factors and prevention of lung cancer. Curr Opin Oncol 1993; 5: 302-309.
26. Carney DN. Lung cancer biology. Curr Opin Oncol 1991; 3: 288-296.
27. Berendsen HH, De Leij L, Poppema S et al. Clinical characterization of non-small-cell lung cancer tumours show neuroendocrine differentiation features. J Clin Oncol 1989; 7: 1614-1620.
28. Skov BG, Sorensen JB, Hirsch FR, Lasson LI, Hansen HH. Prognostic impact of histologic demonstration of chromogranin A and neuronspecific enolase in pulmonary adenocarcinoma. Ann Oncol 1991; 2: 355-360.
29. Slebos RJC, Kibbaelaar RE, Dalesio O et al. K-ras oncogene activation as a prognostic maker in adenocarcinoma of the lung. N Eng; J Med 1990; 32: 561-565.
30. Rodenhuis S, Slebos RJC. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 1992; 52: Suppl 6: 2665s-2669s.
31. Duhaylongsod FG, Lowe VJ, Patz EF Jr, et al. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FGD PET). J Thor Cardiovasc Surg, 1995; 110: 130-139; and discussion 139-140.
32. Scott WJ, Schwabe IL, Gupta NC et al. PET of lung tumors and mediastinal lymph nodes using FGD. Ann Thor Sur 1994; 58: 698-703.
33. Hubner KF, Buonocore E, Singh SK et al. Characterization of chest masses by FGD PET. Clin Nucl Med 1995; 20: 293-298.
34. Dewan NA, Reeb SD, Gupta NC, Gobar LS, Scott WJ. PET-FDG imaging and trans-thoracic needle lung aspiration biopsy in evaluation of pulmonary lesions: a Chest 1995; 108: 441-446.